We showed that both LTβR monotherapy and STING–LTβR combination therapy induced TLS in primary KPC tumors; however, only combination therapy significantly increased activated B cells and memory B cells in the tumors, and combination therapy provided much stronger protection against the second tumor challenge than LTβR monotherapy. The gene discussed is LTBR; the disease is neoplasm.